Amy Reilly joined Crescent in March 2025 as chief communications officer, bringing nearly 25 years of experience in the life science industry to her role, including managing investor relations, executing pipeline and product communications, building employee communications and engagement programs and expanding corporate philanthropic initiatives. Most recently, Ms. Reilly was senior vice president, head of corporate communications and investor relations at Dyne Therapeutics where she helped execute the company’s initial public offering (IPO) and multiple financings totaling more than $1 billion, and oversaw pipeline and internal communications as well as digital and social media. Prior to that, Ms. Reilly was vice president, communications and investor relations at Kaleido Biosciences, where she supported the company’s IPO and managed executive and employee communications. She previously directed corporate communications at ImmunoGen, which was later acquired by AbbVie; led philanthropy and employee communications at Cubist Pharmaceuticals until its acquisition by Merck; and held various roles of increasing responsibility at Biogen. Ms. Reilly received her AB in English and American Literature from Bowdoin College.